Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Geovax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus (HIV), as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeoVax Labs advances cancer therapies and COVID-19 vaccine development

GeoVax Labs showcased advancements in cancer therapies and COVID-19 vaccine development, underlining a commitment to innovation and global healthcare improvement.
While facing financial challenges due to increased R&D expenses and net loss, GeoVax's strategic strengths in vaccine development and clinical trials offer promising opportunities for growth.
The completion of the Gedeptin trial, ongoing Phase II trials for CM04S1, and plans for future vaccine developments position GeoVax for impactful contributions to healthcare.

GeoVax Labs reports Q2 loss, progresses in key trials

GeoVax's Q2 performance reflects ongoing investment in R&D and progress in key clinical trials.
The company's strengths lie in securing funding, commitment to innovation, and vaccine differentiation.
Challenges include recruitment issues, funding needs, and uncertainties in the pipeline.
Opportunities exist in fundraising, vaccine development, expanding indications, and optimizing clinical trials.

GeoVax Labs reports Q3 progress with vaccine trials and financial challenges

GeoVax Labs' Q3 performance reflects a mix of achievements and challenges, with a focus on advancing vaccine candidates and managing financials. The company's strengths in innovation and clinical trial strategies position it well for future growth opportunities through partnerships and regulatory advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Conference call to be held Thursday, May 6, at 4:30 p.m. Eastern Time

GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update

Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide

GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript

COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains

GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update

Conference call to be held Wednesday, March 24, at 8:00 a.m. Eastern Time

GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update

GeoVax Chairman & CEO David Dodd to Present Corporate Overview

GeoVax to Participate in Maxim Group's Inaugural Emerging Growth Virtual Conference

Filings Made in Corporate Focus Areas of SARS-CoV-2 and Immuno-Oncology

GeoVax Expands and Strengthens Intellectual Property Portfolio

Virtual Conference to be Held March 9-10, 2021

GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference

Atlanta, GA, Feb. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the closing of its bought deal offering of 1,644,000 shares of its common stock, which included 204,000 shares sold pursuant to the full exercise of the underwriter's option to purchase additional shares, at a price to the public of $6.25, less underwriting discounts and commissions.  The gross proceeds from the offering were approximately $10.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.

GeoVax Announces Closing of $10.3 Million Bought Deal Offering

ATLANTA, GA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that it has entered into an underwriting agreement with Maxim Group LLC under which the underwriter has agreed to purchase, on a firm commitment basis, 1,440,000 shares of common stock of the Company, at a price to the public of $6.25 per share less underwriting discounts and commissions.  The gross proceeds from the offering are expected to be approximately $9.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.

GeoVax Announces Pricing of $9.0 Million Bought Deal Offering

GeoVax (NASDAQ: GOVX) shares are trading sharply higher on Monday after the company announced it was awarded an NIH grant to advance its COVID-19 vaccine development. GeoVax is a U.S.-based clinical-stage biotechnology company.

GeoVax Spikes 80% On COVID-19 Research Grant Report

Company Focused on Single-dose Vaccine Against Multiple COVID Strains

GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development

GeoVax Also Participating in BIO@JPM During “J.P. Morgan Week 2021”

GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

GeoVax Labs, Inc.'s (GOVX) CEO David Dodd on Q3 2020 Results - Earnings Call Transcript

Public Offering Completed in September 2020 Provides Resources to Accelerate COVID-19 Vaccine and Immuno-Oncology Programs

GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update

Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time

GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update

ATLANTA, GA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announces that CEO and Chairman David Dodd will participate in an upcoming virtual webinar titled, “What COVID-19 Vaccines Teach Us About All Tech Transfers.” Sponsored by Outsourced Pharma (www.outsourcedpharma.com), the event will be held on Wednesday, November 4, 2020 at 2:00pm ET.  Discussion topics include the lessons learned and best practices from the COVID-19 vaccine efforts that can be applied to technology transfers.

GeoVax CEO David Dodd to Participate in Virtual Webinar Hosted by Outsourced Pharma

GeoVax Labs (GOVX) news for Monday includes a deal with the National Institutes of Health to develop a vaccine for the novel coronavirus. The post GeoVax Labs News: GOVX Stock Flies 18% on NIH COVID-19 Deal appeared first on InvestorPlace.

GeoVax Labs News: GOVX Stock Flies 18% on NIH COVID-19 Deal

Shares of GeoVax Labs Inc. were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National Institutes of Health for COVID-19 vaccine development. As part of the agreement, the clinical-stage company said it will get access to patent rights in the virus' spike protein and has non-exclusive rights to develop a COVID-19 vaccine.

GeoVax shares rise on NIH vaccine deal

ATLANTA, GA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a Patent and Biological Materials License Agreement (the “License Agreement”) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), in support of GeoVax's development of a vaccine against SARS-CoV-2,  the virus that causes COVID-19. The Patent License Agreement to GeoVax includes access to NIAID's patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue. 

GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development

ATLANTA, GA, Sept.  29, 2020  (GLOBE NEWSWIRE) --  via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the closing of its underwritten public offering of 2,560,000 units of its common stock, pre-funded warrants, and warrants for gross proceeds of $12.8 million before deducting underwriting discounts and commissions and other estimated offering expenses. 

GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq

ATLANTA, GA, Sept.  24, 2020  (GLOBE NEWSWIRE) -- via  NewMediaWire  -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the pricing of its underwritten public offering of 2,560,000 units at a price to the public of $5.00 per unit. Each unit issued in the offering consists of one share of common stock (or pre-funded warrant to purchase common stock in lieu thereof) and one warrant to purchase one share of common stock at an exercise price of $5.00.

News for Geovax Labs Stock (GOVX)